EA016052B1 - N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ - Google Patents

N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ Download PDF

Info

Publication number
EA016052B1
EA016052B1 EA200701180A EA200701180A EA016052B1 EA 016052 B1 EA016052 B1 EA 016052B1 EA 200701180 A EA200701180 A EA 200701180A EA 200701180 A EA200701180 A EA 200701180A EA 016052 B1 EA016052 B1 EA 016052B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
compound
bis
benzyloxycarbonyl
ethyl
Prior art date
Application number
EA200701180A
Other languages
English (en)
Russian (ru)
Other versions
EA200701180A1 (ru
Inventor
Уилльям А. Боуланджер
Стивен Дж. Колиер
Стивен А. Истам
Деннис Л. Иди
Ронан И. Гевель
Педро Э. Эрнандес-Абад
Джейсон Р. Херр
Ханс Й. Кьэрсгорд
Харолд Меклер
Роберт Э. Поломски
Стивен Р. Шоу
Павел Э. Жичкин
Original Assignee
Телик, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Телик, Инк. filed Critical Телик, Инк.
Publication of EA200701180A1 publication Critical patent/EA200701180A1/ru
Publication of EA016052B1 publication Critical patent/EA016052B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/26—Amides of acids of phosphorus containing P-halide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200701180A 2004-12-21 2005-11-23 N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ EA016052B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/018,391 US8198247B2 (en) 2004-12-21 2004-12-21 Process for and intermediates in the preparation of canfosfamide and its salts
PCT/US2005/042693 WO2006068769A1 (en) 2004-12-21 2005-11-23 Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents

Publications (2)

Publication Number Publication Date
EA200701180A1 EA200701180A1 (ru) 2008-04-28
EA016052B1 true EA016052B1 (ru) 2012-01-30

Family

ID=36216909

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701180A EA016052B1 (ru) 2004-12-21 2005-11-23 N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ

Country Status (15)

Country Link
US (2) US8198247B2 (enExample)
EP (1) EP1827605B1 (enExample)
JP (1) JP5060306B2 (enExample)
KR (1) KR20070089795A (enExample)
CN (1) CN101080251B (enExample)
AR (1) AR052167A1 (enExample)
AU (1) AU2005319579B2 (enExample)
BR (1) BRPI0519141A2 (enExample)
CA (1) CA2587088A1 (enExample)
EA (1) EA016052B1 (enExample)
IL (1) IL182835A0 (enExample)
MX (1) MX2007007215A (enExample)
TW (1) TW200633717A (enExample)
WO (1) WO2006068769A1 (enExample)
ZA (1) ZA200704318B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324426B2 (en) 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
US20100056825A1 (en) * 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
CA2733732A1 (en) * 2011-02-25 2012-08-25 Telik, Inc. Formulations of canfosfamide and their preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
AU766515B2 (en) * 1998-04-16 2003-10-16 Teijin Limited Glutathione derivatives and dosage forms thereof
US6417397B1 (en) * 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
UA74574C2 (en) 2000-05-02 2006-01-16 Telik Inc Bis (n,n'-bis(2-halogenethyl)amino)phosphodiamates, a method for producing thereof (variants), a pharmaceutical composition containing them, and a method for the treatment of tumors
US6506739B1 (en) * 2001-05-01 2003-01-14 Telik, Inc. Bis-(N,N'-bis-(2-haloethyl)amino)phosphoramidates as antitumor agents
NZ555362A (en) * 2005-01-06 2009-05-31 Telik Inc Tripeptide and tetrapeptide thioethers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CIACCIO P.J. ET AL.: "MODULATION OF DETOXIFICATION GENE EXPRESSION IN HUMAN COLON HT29 CELLS BY GLUTATHIONE-S-TRANSFERASE INHIBITORS" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 48, no. 4, 1 October 1995 (1995-10-01), pages 639-647, XP000601686 ISSN: 0026-895X figure 1 *
LYTTLE M.H. ET AL.: "GLUTATHIONE-S-TRANSFERASE ACTIVATES NOVEL ALKYLATING AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 10, 1994, pages 1501-1507, XP000652018 ISSN: 0022-2623 cited 1n the application figure 8 figure 8 page 1503, column 2, lines 1-9 from the bottom page 1506, column 2; figure 8; compounds 16, 17 *
MCINTYRE J.A. ET AL.: "Canfosfamide hydrochloride - Oncolytic - DNA alkylating drug" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 29, no. 10, October 2004 (2004-10), pages 985-991, XP002345162 ISSN: 0377-8282 page 987, column 2 - page 989, column 1 page 1, column 2 scheme 1 *

Also Published As

Publication number Publication date
CN101080251A (zh) 2007-11-28
IL182835A0 (en) 2007-08-19
US20120238772A1 (en) 2012-09-20
JP5060306B2 (ja) 2012-10-31
EP1827605B1 (en) 2014-03-26
US8198247B2 (en) 2012-06-12
WO2006068769A1 (en) 2006-06-29
ZA200704318B (en) 2008-09-25
JP2008524327A (ja) 2008-07-10
AR052167A1 (es) 2007-03-07
TW200633717A (en) 2006-10-01
CA2587088A1 (en) 2006-06-29
MX2007007215A (es) 2007-08-14
EP1827605A1 (en) 2007-09-05
US20060135409A1 (en) 2006-06-22
EA200701180A1 (ru) 2008-04-28
BRPI0519141A2 (pt) 2008-12-30
CN101080251B (zh) 2012-08-29
AU2005319579A1 (en) 2006-06-29
AU2005319579B2 (en) 2011-07-21
US8334266B2 (en) 2012-12-18
KR20070089795A (ko) 2007-09-03

Similar Documents

Publication Publication Date Title
AU2020286278B2 (en) Compositions and methods for inhibiting arginase activity
EP3362443B1 (en) Compounds useful as immunomodulators
DK3041468T3 (en) CYCLIC PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS
CA3035697A1 (en) Biaryl compounds useful as immunomodulators
WO2021068952A1 (zh) 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物
UA75450C2 (en) Use of polysaccharide conjugates for inhibiting metastasis or preventing recurrence of malignant tumor
UA108194C2 (uk) Спосіб отримання (+)-1,4-дигідро-7-[(3s,4s)-3-метокси-4-(метиламіно)-1-піролідиніл]-4-оксо-1-(2-тіазоліл)-1,8-нафтиридин-3-карбонової кислоти
WO2017198194A1 (zh) 一种硼酸和硼酸酯类化合物及其应用
JPH05505820A (ja) 新規化合物
MX2011001800A (es) Compuestos de arsenico organico y metodos para el tratamiento de cancer.
CN104718190B (zh) 用于光动力疗法的吡啶酮化合物
EA016052B1 (ru) N-α-(БЕНЗИЛОКСИКАРБОНИЛ)-L-γ-ГЛУТАМИЛ-3-[[2-[[БИС[БИС(2-ХЛОРЭТИЛ)АМИНО]ФОСФОНИЛ]ОКСИ]ЭТИЛ]СУЛЬФОНИЛ]-L-АЛАНИЛ-2(R)-ФЕНИЛГЛИЦИН ИЛИ ЕГО СОЛЬ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО СОЕДИНЕНИЕ, ПРИМЕНЕНИЕ ЭТОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА И СПОСОБ ЛЕЧЕНИЯ РАКА С ПОМОЩЬЮ ЭТОГО СОЕДИНЕНИЯ
CN105481946A (zh) 5-氨基酮戊酸与3-羟基吡啶-4-酮的缀合物及其制备法和用途
CA3197570A1 (en) Small molecules for the treatment of primary cancer and cancer metastasis
US7960420B2 (en) Diazonamide analogs with improved solubility
CN109053782A (zh) 多功能靶向免疫小分子抗癌药枸橼酸Bestazomib及其制备方法与应用
RU2697551C2 (ru) Новые производные peg
EP4204428A1 (en) 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto
KR20220161407A (ko) 면역조정제
JP7154528B2 (ja) ホウ素含有葉酸誘導体
JP5249753B2 (ja) ジカルボン酸誘導体、転移阻害剤および抗腫瘍調製物の化学療法活性を増大する薬剤、細胞増殖抑制剤の効果を増大する方法および転移プロセスの阻害のための方法
CN106146612A (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
CN116731305A (zh) 一种抗肿瘤大环内酯聚合物及其制备方法和应用
WO2015158306A1 (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
CN104987296A (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的芥子类化合物及其相关化合物的前药

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU